Evidence map›Paper›PMID 19142939›Full record

ReviewAngewandte Chemie (International ed. in English)2009

Nanomedicine--challenge and perspectives.

Kristina Riehemann, Stefan W Schneider, Thomas A Luger, Biana Godin, Mauro Ferrari, Harald Fuchs

Abstract readReview
In one paragraph

Review in Angewandte Chemie (International ed. in English), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 278 papers.

0numbers the graph read from it
0cells of the map it votes in
278citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

278 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

218 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristina RiehemannCenter for Nanotechnology und Physikalisches Institut, Westfälische Wilhelms-Universität Münster, Wilhelm-Klemm-Strasse 10, 48149 Münster, Germany. k.riehemann@uni-muenster.de
Stefan W Schneider
Thomas A Luger
Biana Godin
Mauro Ferrari
Harald Fuchs

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
Nanovectors for Characterization and Destruction of Breast Tumor VasculatureR01CA128797 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2007 to 2010
$1.7M
NCI NIH HHS R01 CA128797NCI NIH HHS U54 CA143837PHS HHS R01A128797
6 · The paper itself

Abstract

The application of nanotechnology concepts to medicine joins two large cross-disciplinary fields with an unprecedented societal and economical potential arising from the natural combination of specific achievements in the respective fields. The common basis evolves from the molecular-scale properties relevant to the two fields. Local probes and molecular imaging techniques allow surface and interface properties to be characterized on a nanometer scale at predefined locations, while chemical approaches offer the opportunity to elaborate and address surfaces, for example, for targeted drug delivery, enhanced biocompatibility, and neuroprosthetic purposes. However, concerns arise in this cross-disciplinary area about toxicological aspects and ethical implications. This Review gives an overview of selected recent developments and applications of nanomedicine.

Indexed as

NanomedicineAnimalsBiocompatible MaterialsDiagnostic Uses of ChemicalsDrug-Related Side Effects and Adverse ReactionsHumansNanoparticlesPharmaceutical PreparationsSurface PropertiesBiocompatible MaterialsDiagnostic Uses of ChemicalsPharmaceutical Preparations

Identifiers

PMID19142939
PMCPMC4175737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.